Product image of Mifoglame (Sitagliptin) supplied by GNH India

Mifoglame

Active Ingredient:
Sitagliptin
Origin:
EU

Mifoglame (Sitagliptin)

Sitagliptin, the active ingredient in Mifoglame, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral administration. It works by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon release, which helps lower blood glucose levels in adults diagnosed with type 2 diabetes mellitus.

GNH India supplies Mifoglame as a licensed, Good Distribution Practice‑compliant pharmaceutical product, providing reliable international sourcing for hospitals, pharmacies and clinics that require quality‑assured antidiabetic medicines across global markets and consistent supply chains.

Manufacturer / TM Owner

Bausch Health Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mifoglame (sitagliptin) belongs to the DPP‑4 inhibitor class used to manage disorders of glucose metabolism.

  • Type 2 diabetes mellitus: improves glycemic control when used with diet and exercise.
  • Combination therapy: added to metformin, sulfonylureas or insulin to achieve target HbA1c.
  • Monotherapy: can be prescribed as initial oral treatment for patients inadequately controlled on lifestyle alone.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 enzyme, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced post‑prandial and fasting blood glucose concentrations.

Side Effects

Mifoglame is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: transient cranial discomfort.
  • Upper respiratory tract infection: symptoms of cold or flu.
  • Nasopharyngitis: sore throat and nasal congestion.
  • Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Joint pain: unexplained arthralgia.
  • Hypersensitivity: skin eruptions or eosinophilia.
  • Hepatic injury: elevated liver enzymes.
  • Severe hypoglycemia: when combined with insulin or sulfonylureas.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Hypoglycemia risk: monitor blood glucose when combined with insulin or sulfonylureas.
  • History of pancreatitis: avoid use in patients with prior pancreatic inflammation.
  • Pregnancy and lactation: prescribe only if potential benefit justifies potential risk.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Sitagliptin may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Insulin: increased risk of hypoglycemia.
  • Sulfonylureas: additive hypoglycemic effect.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely)

  • Diuretics: possible alteration of glucose control.
  • Rifampin: may reduce sitagliptin exposure.
  • ACE inhibitors: monitor renal function and electrolytes.
  • Digoxin: observe for potential changes in serum concentration.

Frequently Asked Questions

Mifoglame contains sitagliptin, a DPP‑4 inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas or insulin.

Sitagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels.

The prescribed dose of sitagliptin is determined by the treating physician based on the patient’s renal function, glycemic targets and concomitant therapies. Clinicians follow local prescribing guidelines and adjust the regimen as needed.

Safety data for sitagliptin during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under medical supervision.

To request Mifoglame, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower intrinsic risk of hypoglycemia because its insulin‑stimulating effect is glucose‑dependent. Unlike metformin, it does not cause gastrointestinal upset, but it does not have the same weight‑loss benefit. It is generally considered a well‑tolerated option within the DPP‑4 inhibitor class.

Mifoglame tablets should be stored at room temperature, below 25 °C, in the original blister pack or bottle. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Mifoglame is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events to monitor are acute pancreatitis, severe allergic reactions such as anaphylaxis, and significant hypoglycemia when sitagliptin is combined with insulin or sulfonylureas. Prompt medical attention is required if any of these occur.

Mifoglame is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is advised for individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²) and those with a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT